--Lead type V editor program in SCD demonstrates industry leading delivery and repeat dosing with a passive LNP-- --Results reveal unprecedented improvement of editing rates from single digits to nearly 80% in primary HSPCs-- WATERTOWN, Mass., Oct. 22, 2024 /PRNewswire/ -- Orna...
Orna Therapeutics Unveils Novel In Vivo Gene Editing Data Highlighting Engineering and Delivery Approach at the 31st Annual European Society of Gene & Cell Therapy Congress
Seaking AlphaSeeking Alpha / Seaking Alpha 18 hours ago 1 Views
Comments